APA (7th ed.) Citation

Budczies, J., Romanovsky, E., Kirchner, M., Neumann, O., Blasi, M., Schnorbach, J., . . . Stenzinger, A. (2024). KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma. British journal of cancer, 131(3), . https://doi.org/10.1038/s41416-024-02746-z

Chicago Style (17th ed.) Citation

Budczies, Jan, et al. "KRAS and TP53 Co-mutation Predicts Benefit of Immune Checkpoint Blockade in Lung Adenocarcinoma." British Journal of Cancer 131, no. 3 (2024). https://doi.org/10.1038/s41416-024-02746-z.

MLA (9th ed.) Citation

Budczies, Jan, et al. "KRAS and TP53 Co-mutation Predicts Benefit of Immune Checkpoint Blockade in Lung Adenocarcinoma." British Journal of Cancer, vol. 131, no. 3, 2024, https://doi.org/10.1038/s41416-024-02746-z.